Download PDF
Semin Neurol 2016; 36(01): 020-028
DOI: 10.1055/s-0035-1571214
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Botulinum Toxin Treatment of Autonomic Disorders: Focal Hyperhidrosis and Sialorrhea

Christine Hosp
1   Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
,
Markus K. Naumann
2   Department of Neurology, Klinikum Augsburg, Augsburg, Germany
,
Henning Hamm
1   Department of Dermatology, Venereology and Allergology, University Hospital Würzburg, Würzburg, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
11 February 2016 (online)

    Permissions and Reprints

Abstract

Primary focal hyperhidrosis is a common autonomic disorder that significantly impacts quality of life. It is characterized by excessive sweating confined to circumscribed areas, such as the axillae, palms, soles, and face. Less frequent types of focal hyperhidrosis secondary to underlying causes include gustatory sweating in Frey's syndrome and compensatory sweating in Ross' syndrome and after sympathectomy. Approval of onabotulinumtoxinA for severe primary axillary hyperhidrosis in 2004 has revolutionized the treatment of this indication. Meanwhile further type A botulinum neurotoxins like abobotulinumtoxinA and incobotulinumtoxinA, as well as the type B botulinum neurotoxin rimabotulinumtoxinB are successfully used off-label for axillary and various other types of focal hyperhidrosis. For unexplained reasons, the duration of effect differs considerably at different sites. Beside hyperhidrosis, botulinum neurotoxin is also highly valued for the treatment of sialorrhea affecting patients with Parkinson's disease, cerebral palsy, amyotrophic lateral sclerosis, motor neuron disease, and other neurologic conditions. With correct dosing and application, side effects are manageable and transient.

Keywords

botulinum neurotoxin - focal hyperhidrosis - sweating - sialorrhea - autonomic disorders
 

  • References

  • 1 Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol 2004; 51 (2) 241-248
    CrossrefPubMedGoogle Scholar
  • 2 Rosell K, Hymnelius K, Swartling C. Botulinum toxin type A and B improve quality of life in patients with axillary and palmar hyperhidrosis. Acta Derm Venereol 2013; 93 (3) 335-339
    CrossrefPubMedGoogle Scholar
  • 3 Kouris A, Armyra K, Christodoulou C, Karimali P, Karypidis D, Kontochristopoulos G. Quality of life in patients with focal hyperhidrosis before and after treatment with botulinum toxin A. ISRN Dermatol 2014; 2014: 308650
    PubMedGoogle Scholar
  • 4 Hamm H. Impact of hyperhidrosis on quality of life and its assessment. Dermatol Clin 2014; 32 (4) 467-476
    CrossrefPubMedGoogle Scholar
  • 5 Hamm H, Naumann MK. Hyperhidrosis. In: Truong D, Hallett M, Zachary C, Dressler D, , eds. Handbook of Botulinum Toxin Therapy. 2nd ed. Cambridge: Cambridge University Press; 2013: 194-202
    Google Scholar
  • 6 Stashak AB, Brewer JD. Management of hyperhidrosis. Clin Cosmet Investig Dermatol 2014; 7: 285-299
    PubMedGoogle Scholar
  • 7 Lear W, Kessler E, Solish N, Glaser DA. An epidemiological study of hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S69-S75
    CrossrefPubMedGoogle Scholar
  • 8 Lakraj AA, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel) 2013; 5 (4) 821-840
    CrossrefPubMedGoogle Scholar
  • 9 Lee KY, Levell NJ. Turning the tide: a history and review of hyperhidrosis treatment. JRSM Open 2014; 5 (1) 2042533313505511
    PubMedGoogle Scholar
  • 10 Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg 2012; 55 (6) 1696-1700
    CrossrefPubMedGoogle Scholar
  • 11 Ibrahim O, Kakar R, Bolotin D , et al. The comparative effectiveness of suction-curettage and onabotulinumtoxin-A injections for the treatment of primary focal axillary hyperhidrosis: a randomized control trial. J Am Acad Dermatol 2013; 69 (1) 88-95
    CrossrefPubMedGoogle Scholar
  • 12 Hong HC, Lupin M, O'Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg 2012; 38 (5) 728-735
    CrossrefPubMedGoogle Scholar
  • 13 Lee SJ, Chang KY, Suh DH, Song KY, Ryu HJ. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther 2013; 15 (5) 255-259
    CrossrefPubMedGoogle Scholar
  • 14 Atkinson JL, Fode-Thomas NC, Fealey RD, Eisenach JH, Goerss SJ. Endoscopic transthoracic limited sympathotomy for palmar-plantar hyperhidrosis: outcomes and complications during a 10-year period. Mayo Clin Proc 2011; 86 (8) 721-729
    CrossrefPubMedGoogle Scholar
  • 15 Benson RA, Palin R, Holt PJ, Loftus IM. Diagnosis and management of hyperhidrosis. BMJ 2013; 347: f6800
    CrossrefPubMedGoogle Scholar
  • 16 Naumann M, Hofmann U, Bergmann I, Hamm H, Toyka KV, Reiners K. Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin. Arch Dermatol 1998; 134 (3) 301-304
    CrossrefPubMedGoogle Scholar
  • 17 Dressler D, Adib Saberi F. Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox(®) doses. J Neural Transm (Vienna) 2013; 120 (11) 1565-1567
    CrossrefPubMedGoogle Scholar
  • 18 Baumann L, Slezinger A, Halem M , et al. Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosis. Dermatol Surg 2005; 31 (3) 263-270
    CrossrefPubMedGoogle Scholar
  • 19 Brin MF, James C, Maltman J. Botulinum toxin type A products are not interchangeable: a review of the evidence. Biologics 2014; 8: 227-241
    PubMedGoogle Scholar
  • 20 Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 2013; 120 (2) 275-290
    CrossrefPubMedGoogle Scholar
  • 21 Naumann M, Carruthers A, Carruthers J , et al. Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications. Mov Disord 2010; 25 (13) 2211-2218
    CrossrefPubMedGoogle Scholar
  • 22 Dressler D. Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol 2013; 260 (3) 701-713
    CrossrefPubMedGoogle Scholar
  • 23 Kouris A, Agiasofitou E, Gregoriou S, Sofouri E, Kontochristopoulos G, Panagopoulos G. Generalized neurological symptoms following treatment of focal hyperhidrosis with botulinum toxin A. Int J Dermatol 2014; 53 (11) e544-e547
    CrossrefPubMedGoogle Scholar
  • 24 Chiarello D, Piombo M, Corbetto M , et al. Relapsing-remitting severe generalized muscular weakness after botulinum toxin treatment for hyperhidrosis. Muscle Nerve 2014; 50 (3) 456-457
    CrossrefPubMedGoogle Scholar
  • 25 Ghasemi M, Norouzi R, Salari M, Asadi B. Iatrogenic botulism after the therapeutic use of botulinum toxin-A: a case report and review of the literature. Clin Neuropharmacol 2012; 35 (5) 254-257
    CrossrefPubMedGoogle Scholar
  • 26 Baumann LS, Halem ML. Systemic adverse effects after botulinum toxin type B (Myobloc) injections for the treatment of palmar hyperhidrosis. Arch Dermatol 2003; 139 (2) 226-227
    CrossrefPubMedGoogle Scholar
  • 27 Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ 2001; 323 (7313) 596-599
    CrossrefPubMedGoogle Scholar
  • 28 Dressler D, Adib Saberi F, Benecke R. Botulinum toxin type B for treatment of axillar hyperhidrosis. J Neurol 2002; 249 (12) 1729-1732
    CrossrefPubMedGoogle Scholar
  • 29 Dressler D, Benecke R. Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. Eur Neurol 2003; 49 (1) 34-38
    CrossrefPubMedGoogle Scholar
  • 30 Baumann L, Slezinger A, Halem M , et al. Pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for treatment of axillary hyperhidrosis. Int J Dermatol 2005; 44 (5) 418-424
    CrossrefPubMedGoogle Scholar
  • 31 Karlqvist M, Rosell K, Rystedt A, Hymnelius K, Swartling C. Botulinum toxin B in the treatment of craniofacial hyperhidrosis. J Eur Acad Dermatol Venereol 2014; 28 (10) 1313-1317
    CrossrefPubMedGoogle Scholar
  • 32 Hosp C, Naumann MK, Hamm H. [Botulinum toxin in focal hyperhidrosis. An update]. Hautarzt 2012; 63 (6) 469-476
    CrossrefPubMedGoogle Scholar
  • 33 Tan M, Kim E, Koren G, Bozzo P. Botulinum toxin type A in pregnancy. Can Fam Physician 2013; 59 (11) 1183-1184
    PubMedGoogle Scholar
  • 34 Heckmann M, Ceballos-Baumann AO, Plewig G ; Hyperhidrosis Study Group. Botulinum toxin A for axillary hyperhidrosis (excessive sweating). N Engl J Med 2001; 344 (7) 488-493
    CrossrefPubMedGoogle Scholar
  • 35 Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol 2007; 156 (5) 986-989
    CrossrefPubMedGoogle Scholar
  • 36 Talarico-Filho S, Mendonça DO Nascimento M, Sperandeo DE Macedo F, DE Sanctis Pecora C. A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S44-S50
    CrossrefPubMedGoogle Scholar
  • 37 Dressler D. Comparing Botox and Xeomin for axillar hyperhidrosis. J Neural Transm (Vienna) 2010; 117 (3) 317-319
    CrossrefPubMedGoogle Scholar
  • 38 Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY ; North American Botox in Primary Axillary Hyperhidrosis Clinical Study Group. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol 2007; 56 (4) 604-611
    CrossrefPubMedGoogle Scholar
  • 39 Naumann M, Dressler D, Hallett M , et al. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders. Toxicon 2013; 67: 141-152
    CrossrefPubMedGoogle Scholar
  • 40 Lowe N, Campanati A, Bodokh I , et al. The place of botulinum toxin type A in the treatment of focal hyperhidrosis. Br J Dermatol 2004; 151 (6) 1115-1122
    CrossrefPubMedGoogle Scholar
  • 41 Naumann M, Lowe NJ, Kumar CR, Hamm H ; Hyperhidrosis Clinical Investigators Group. Botulinum toxin type A is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective study. Arch Dermatol 2003; 139 (6) 731-736
    CrossrefPubMedGoogle Scholar
  • 42 Naumann MK, Hamm H, Lowe NJ ; Botox Hyperhidrosis Clinical Study Group. Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial. Br J Dermatol 2002; 147 (6) 1218-1226
    CrossrefPubMedGoogle Scholar
  • 43 Lowe PL, Cerdan-Sanz S, Lowe NJ. Botulinum toxin type A in the treatment of bilateral primary axillary hyperhidrosis: efficacy and duration with repeated treatments. Dermatol Surg 2003; 29 (5) 545-548
    PubMedGoogle Scholar
  • 44 D'Epiro S, Macaluso L, Salvi M , et al. Safety and prolonged efficacy of botulin toxin A in primary hyperhidrosis. Clin Ter 2014; 165 (6) e395-e400
    PubMedGoogle Scholar
  • 45 Lecouflet M, Leux C, Fenot M, Célerier P, Maillard H. Duration of efficacy increases with the repetition of botulinum toxin A injections in primary axillary hyperhidrosis: a study in 83 patients. J Am Acad Dermatol 2013; 69 (6) 960-964
    CrossrefPubMedGoogle Scholar
  • 46 Schnider P, Binder M, Auff E, Kittler H, Berger T, Wolff K. Double-blind trial of botulinum A toxin for the treatment of focal hyperhidrosis of the palms. Br J Dermatol 1997; 136 (4) 548-552
    CrossrefPubMedGoogle Scholar
  • 47 Lowe NJ, Yamauchi PS, Lask GP, Patnaik R, Iyer S. Efficacy and safety of botulinum toxin type A in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled study. Dermatol Surg 2002; 28 (9) 822-827
    CrossrefPubMedGoogle Scholar
  • 48 Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosis. Br J Dermatol 2003; 149 (5) 1041-1045
    CrossrefPubMedGoogle Scholar
  • 49 Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology 2001; 57 (11) 2095-2099
    CrossrefPubMedGoogle Scholar
  • 50 Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38 (2 Pt 1): 227-229
    CrossrefPubMedGoogle Scholar
  • 51 Solomon BA, Hayman R. Botulinum toxin type A therapy for palmar and digital hyperhidrosis. J Am Acad Dermatol 2000; 42 (6) 1026-1029
    CrossrefPubMedGoogle Scholar
  • 52 Naver H, Swartling C, Aquilonius SM. Palmar and axillary hyperhidrosis treated with botulinum toxin: one-year clinical follow-up. Eur J Neurol 2000; 7 (1) 55-62
    CrossrefPubMedGoogle Scholar
  • 53 Ito K, Yanagishita T, Ohshima Y, Tamada Y, Watanabe D. Therapeutic effectiveness of botulinum toxin type A based on severity of palmar hyperhidrosis. J Dermatol 2011; 38 (9) 859-863
    PubMedGoogle Scholar
  • 54 El Kahky HM, Diab HM, Aly DG, Farag NM. Efficacy of onabotulinum toxin A (Botox) versus abobotulinum toxin A (Dysport) using a conversion factor (1 : 2.5) in treatment of primary palmar hyperhidrosis. Dermatol Res Pract 2013; 2013: 686329
    PubMedGoogle Scholar
  • 55 Kinkelin I, Hund M, Naumann M, Hamm H. Effective treatment of frontal hyperhidrosis with botulinum toxin A. Br J Dermatol 2000; 143 (4) 824-827
    CrossrefPubMedGoogle Scholar
  • 56 Doft MA, Hardy KL, Ascherman JA. Treatment of hyperhidrosis with botulinum toxin. Aesthet Surg J 2012; 32 (2) 238-244
    CrossrefPubMedGoogle Scholar
  • 57 Lowe PL, Lowe NJ. Botulinum toxin type B: pH change reduces injection pain, retains efficacy. Dermatol Surg 2014; 40 (12) 1328-1333
    CrossrefPubMedGoogle Scholar
  • 58 Campanati A, Giuliodori K, Martina E, Giuliano A, Ganzetti G, Offidani A. Onabotulinumtoxin type A (Botox(®)) versus incobotulinumtoxin type A (Xeomin(®)) in the treatment of focal idiopathic palmar hyperhidrosis: results of a comparative double-blind clinical trial. J Neural Transm (Vienna) 2014; 121 (1) 21-26
    CrossrefPubMedGoogle Scholar
  • 59 Basciani M, Di Rienzo F, Bizzarrini M, Zanchi M, Copetti M, Intiso D. Efficacy of botulinum toxin type B for the treatment of primary palmar hyperhidrosis: a prospective, open, single-blind, multi-centre study. Arch Dermatol Res 2014; 306 (5) 497-503
    PubMedGoogle Scholar
  • 60 Campanati A, Lagalla G, Penna L, Gesuita R, Offidani A. Local neural block at the wrist for treatment of palmar hyperhidrosis with botulinum toxin: technical improvements. J Am Acad Dermatol 2004; 51 (3) 345-348
    CrossrefPubMedGoogle Scholar
  • 61 Paracka L, Kollewe K, Dengler R, Dressler D. Botulinum toxin therapy for hyperhidrosis: reduction of injection site pain by nitrous oxide/oxygen mixtures. J Neural Transm (Vienna) 2015; 122 (9) 1279-1282
    CrossrefPubMedGoogle Scholar
  • 62 Li M, Goldberger BA, Hopkins C. Fatal case of BOTOX-related anaphylaxis?. J Forensic Sci 2005; 50 (1) 169-172
    PubMedGoogle Scholar
  • 63 Campanati A, Bernardini ML, Gesuita R, Offidani A. Plantar focal idiopathic hyperhidrosis and botulinum toxin: a pilot study. Eur J Dermatol 2007; 17 (1) 52-54
    PubMedGoogle Scholar
  • 64 Vadoud-Seyedi J. Treatment of plantar hyperhidrosis with botulinum toxin type A. Int J Dermatol 2004; 43 (12) 969-971
    CrossrefPubMedGoogle Scholar
  • 65 Glaser DA, Hebert AA, Pariser DM, Solish N. Palmar and plantar hyperhidrosis: best practice recommendations and special considerations. Cutis 2007; 79 (5, Suppl) 18-28
    PubMedGoogle Scholar
  • 66 Benohanian A. Treatment of recalcitrant plantar hyperhidrosis with type-A botulinum toxin injections and aluminum chloride in salicylic acid gel. Dermatol Online J 2008; 14 (2) 5
    PubMedGoogle Scholar
  • 67 Anders D, Moosbauer S, Naumann MK, Hamm H. Craniofacial hyperhidrosis successfully treated with botulinum toxin type A. Eur J Dermatol 2008; 18 (1) 87-88
    PubMedGoogle Scholar
  • 68 Trindade de Almeida AR, Marques E, de Almeida J, Cunha T, Boraso R. Pilot study comparing the diffusion of two formulations of botulinum toxin type A in patients with forehead hyperhidrosis. Dermatol Surg 2007; 33 (1 Spec No.): S37-S43
    CrossrefPubMedGoogle Scholar
  • 69 Naumann M, Zellner M, Toyka KV, Reiners K. Treatment of gustatory sweating with botulinum toxin. Ann Neurol 1997; 42 (6) 973-975
    CrossrefPubMedGoogle Scholar
  • 70 Eckardt A, Kuettner C. Treatment of gustatory sweating (Frey's syndrome) with botulinum toxin A. Head Neck 2003; 25 (8) 624-628
    CrossrefPubMedGoogle Scholar
  • 71 Guntinas-Lichius O. Increased botulinum toxin type A dosage is more effective in patients with Frey's syndrome. Laryngoscope 2002; 112 (4) 746-749
    CrossrefPubMedGoogle Scholar
  • 72 Ng S, Torjek C, Hovan A. Management of Frey syndrome using botulinum neurotoxin: a case report. J Can Dent Assoc 2009; 75 (9) 651-654
    PubMedGoogle Scholar
  • 73 Kreyden OP, Scheidegger EP. Anatomy of the sweat glands, pharmacology of botulinum toxin, and distinctive syndromes associated with hyperhidrosis. Clin Dermatol 2004; 22 (1) 40-44
    CrossrefPubMedGoogle Scholar
  • 74 Martos Díaz P, Bances del Castillo R, Mancha de la Plata M , et al. Clinical results in the management of Frey's syndrome with injections of Botulinum toxin. Med Oral Patol Oral Cir Bucal 2008; 13 (4) E248-E252
    PubMedGoogle Scholar
  • 75 de Bree R, Duyndam JE, Kuik DJ, Leemans CR. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. Arch Otolaryngol Head Neck Surg 2009; 135 (3) 287-290
    CrossrefPubMedGoogle Scholar
  • 76 Cantarella G, Berlusconi A, Mele V, Cogiamanian F, Barbieri S. Treatment of Frey's syndrome with botulinum toxin type B. Otolaryngol Head Neck Surg 2010; 143 (2) 214-218
    CrossrefPubMedGoogle Scholar
  • 77 Bergmann I, Dauphin M, Naumann M , et al. Selective degeneration of sudomotor fibers in Ross syndrome and successful treatment of compensatory hyperhidrosis with botulinum toxin. Muscle Nerve 1998; 21 (12) 1790-1793
    CrossrefPubMedGoogle Scholar
  • 78 Crowner BE, Torres-Russotto D, Carter AR, Racette BA. Systemic weakness after therapeutic injections of botulinum toxin a: a case series and review of the literature. Clin Neuropharmacol 2010; 33 (5) 243-247
    CrossrefPubMedGoogle Scholar
  • 79 Licht PB, Pilegaard HK. Severity of compensatory sweating after thoracoscopic sympathectomy. Ann Thorac Surg 2004; 78 (2) 427-431
    CrossrefPubMedGoogle Scholar
  • 80 Bechara FG, Sand M, Moussa G , et al. Treatment of unilateral compensatory sweating after endoscopical thoracic sympathectomy for general hyperhidrosis with botulinum toxin A. Dermatol Surg 2006; 32 (5) 745-748
    PubMedGoogle Scholar
  • 81 Kim WO, Kil HK, Yoon KB, Noh KU. Botulinum toxin: a treatment for compensatory hyperhidrosis in the trunk. Dermatol Surg 2009; 35 (5) 833-838 , discussion 838
    CrossrefPubMedGoogle Scholar
  • 82 Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C. Fields of anhidrotic effects of abobotulinumtoxinA in patients with compensatory hyperhidrosis. Dermatol Surg 2015; 41 (Suppl. 01) S93-S100
    CrossrefPubMedGoogle Scholar
  • 83 Bechara FG, Sand M, Achenbach RK, Sand D, Altmeyer P, Hoffmann K. Focal hyperhidrosis of the anal fold: successful treatment with botulinum toxin A. Dermatol Surg 2007; 33 (8) 924-927
    PubMedGoogle Scholar
  • 84 Charrow A, DiFazio M, Foster L, Pasquina PF, Tsao JW. Intradermal botulinum toxin type A injection effectively reduces residual limb hyperhidrosis in amputees: a case series. Arch Phys Med Rehabil 2008; 89 (7) 1407-1409
    CrossrefPubMedGoogle Scholar
  • 85 Kern U, Kohl M, Seifert U, Schlereth T. Botulinum toxin type B in the treatment of residual limb hyperhidrosis for lower limb amputees: a pilot study. Am J Phys Med Rehabil 2011; 90 (4) 321-329
    CrossrefPubMedGoogle Scholar
  • 86 Hexsel DM, Dal'forno T, Hexsel CL. Inguinal, or Hexsel's hyperhidrosis. Clin Dermatol 2004; 22 (1) 53-59
    CrossrefPubMedGoogle Scholar
  • 87 Benson J, Daugherty KK. Botulinum toxin A in the treatment of sialorrhea. Ann Pharmacother 2007; 41 (1) 79-85
    PubMedGoogle Scholar
  • 88 Giess R, Werner E, Beck M, Reiners C, Toyka KV, Naumann M. Impaired salivary gland function reveals autonomic dysfunction in amyotrophic lateral sclerosis. J Neurol 2002; 249 (9) 1246-1249
    CrossrefPubMedGoogle Scholar
  • 89 Truong DD, Bhidayasiri R. Evidence for the effectiveness of botulinum toxin for sialorrhoea. J Neural Transm (Vienna) 2008; 115 (4) 631-635
    CrossrefPubMedGoogle Scholar
  • 90 Naumann M, So Y, Argoff CE , et al; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70 (19) 1707-1714
    CrossrefPubMedGoogle Scholar
  • 91 Ellies M, Laskawi R, Tormählen G, Götz W. The effect of local injection of botulinum toxin A on the parotid gland of the rat: an immunohistochemical and morphometric study. J Oral Maxillofac Surg 2000; 58 (11) 1251-1256
    CrossrefPubMedGoogle Scholar
  • 92 Jackson CE, Gronseth G, Rosenfeld J , et al; Muscle Study Group. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009; 39 (2) 137-143
    CrossrefPubMedGoogle Scholar
  • 93 Guidubaldi A, Fasano A, Ialongo T , et al. Botulinum toxin A versus B in sialorrhea: a prospective, randomized, double-blind, crossover pilot study in patients with amyotrophic lateral sclerosis or Parkinson's disease. Mov Disord 2011; 26 (2) 313-319
    CrossrefPubMedGoogle Scholar
  • 94 Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006; 21 (5) 704-707
    CrossrefPubMedGoogle Scholar
  • 95 Lipp A, Trottenberg T, Schink T, Kupsch A, Arnold G. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003; 61 (9) 1279-1281
    CrossrefPubMedGoogle Scholar
  • 96 Mancini F, Zangaglia R, Cristina S , et al. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. Mov Disord 2003; 18 (6) 685-688
    CrossrefPubMedGoogle Scholar
  • 97 Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004; 62 (1) 37-40
    CrossrefPubMedGoogle Scholar
  • 98 Wilken B, Aslami B, Backes H. Successful treatment of drooling in children with neurological disorders with botulinum toxin A or B. Neuropediatrics 2008; 39 (4) 200-204
    Article in Thieme ConnectPubMedGoogle Scholar
  • 99 Chan KH, Liang C, Wilson P, Higgins D, Allen GC. Long-term safety and efficacy data on botulinum toxin type A: an injection for sialorrhea. JAMA Otolaryngol Head Neck Surg 2013; 139 (2) 134-138
    CrossrefPubMedGoogle Scholar
  • 100 Anagnostou E, Rentzos M, Alexakis T, Zouvelou V, Zambelis T, Evdokimidis I. Volume matters: the influence of different botulinum toxin-A dilutions for sialorrhea in amyotrophic lateral sclerosis. Muscle Nerve 2013; 47 (2) 276-278
    CrossrefPubMedGoogle Scholar